IN2014DN09297A - - Google Patents
Info
- Publication number
- IN2014DN09297A IN2014DN09297A IN9297DEN2014A IN2014DN09297A IN 2014DN09297 A IN2014DN09297 A IN 2014DN09297A IN 9297DEN2014 A IN9297DEN2014 A IN 9297DEN2014A IN 2014DN09297 A IN2014DN09297 A IN 2014DN09297A
- Authority
- IN
- India
- Prior art keywords
- nanoparticles
- methods
- octylcyanoacrylate
- exendin
- obesity
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010011459 Exenatide Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 229920001091 Poly(octyl cyanoacrylate) Polymers 0.000 abstract 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 1
- 229960001519 exenatide Drugs 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- -1 poly(octylcyanoacrylate) Polymers 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647633P | 2012-05-16 | 2012-05-16 | |
| PCT/IB2013/000964 WO2013171570A1 (en) | 2012-05-16 | 2013-05-16 | Polypeptide loaded poca nanoparticles for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09297A true IN2014DN09297A (forum.php) | 2015-07-10 |
Family
ID=48577784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9297DEN2014 IN2014DN09297A (forum.php) | 2012-05-16 | 2013-05-16 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150342897A1 (forum.php) |
| EP (1) | EP2849775A1 (forum.php) |
| JP (1) | JP2015523332A (forum.php) |
| KR (1) | KR20150010953A (forum.php) |
| CN (1) | CN104411321A (forum.php) |
| AU (1) | AU2013261214A1 (forum.php) |
| CA (1) | CA2873536A1 (forum.php) |
| IN (1) | IN2014DN09297A (forum.php) |
| RU (1) | RU2014150850A (forum.php) |
| WO (1) | WO2013171570A1 (forum.php) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104799440B (zh) * | 2014-01-23 | 2016-06-08 | 香港纺织及成衣研发中心有限公司 | 改善代谢综合症的功能服及其制造方法 |
| CN105342999A (zh) * | 2014-08-18 | 2016-02-24 | 山东绿叶制药有限公司 | 艾塞那肽口服纳米粒 |
| CN109675020B (zh) * | 2019-01-11 | 2021-05-04 | 浙江大学 | 一种口服glp-1多肽类纳米制剂及其制备方法和应用 |
| US12284984B2 (en) | 2020-12-18 | 2025-04-29 | Spectrum Brands, Inc. | Grooming tool for animal and methods |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2113879T3 (es) | 1990-01-24 | 1998-05-16 | Douglas I Buckley | Analogos de glp-1 utiles para el tratamiento de diabetes. |
| IE80468B1 (en) * | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| WO1998005351A1 (en) | 1996-08-08 | 1998-02-12 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
| AU749914B2 (en) | 1997-08-08 | 2002-07-04 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| WO1999025728A1 (en) | 1997-11-14 | 1999-05-27 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| ATE381939T1 (de) | 1997-11-14 | 2008-01-15 | Amylin Pharmaceuticals Inc | Neuartige exendin agonisten |
| CA2320371C (en) | 1998-02-13 | 2012-01-17 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
| WO1999043708A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| ES2311560T3 (es) | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| DK1463751T3 (da) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Albuminfusionsproteiner. |
| CA2539253A1 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
| CA2611985C (en) | 2005-06-17 | 2016-08-16 | The University Of North Carolina At Chapel Hill | Nanoparticle fabrication methods, systems, and materials |
| US20080138418A1 (en) * | 2006-12-07 | 2008-06-12 | Tong Shen Enterprise Co., Ltd. | Nanoparticles composed of alkyl-cyanoacrylate polymers |
| CN103660089B (zh) | 2007-10-12 | 2017-04-12 | 流体科技公司 | 用于生产颗粒和图案化膜的系统和方法 |
-
2013
- 2013-05-16 AU AU2013261214A patent/AU2013261214A1/en not_active Abandoned
- 2013-05-16 RU RU2014150850A patent/RU2014150850A/ru not_active Application Discontinuation
- 2013-05-16 CN CN201380031679.4A patent/CN104411321A/zh active Pending
- 2013-05-16 CA CA2873536A patent/CA2873536A1/en not_active Abandoned
- 2013-05-16 EP EP13727643.2A patent/EP2849775A1/en not_active Withdrawn
- 2013-05-16 US US14/401,333 patent/US20150342897A1/en not_active Abandoned
- 2013-05-16 WO PCT/IB2013/000964 patent/WO2013171570A1/en not_active Ceased
- 2013-05-16 IN IN9297DEN2014 patent/IN2014DN09297A/en unknown
- 2013-05-16 KR KR20147031771A patent/KR20150010953A/ko not_active Withdrawn
- 2013-05-16 JP JP2015512144A patent/JP2015523332A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20150342897A1 (en) | 2015-12-03 |
| KR20150010953A (ko) | 2015-01-29 |
| CN104411321A (zh) | 2015-03-11 |
| JP2015523332A (ja) | 2015-08-13 |
| WO2013171570A1 (en) | 2013-11-21 |
| EP2849775A1 (en) | 2015-03-25 |
| RU2014150850A (ru) | 2016-07-10 |
| CA2873536A1 (en) | 2013-11-21 |
| AU2013261214A1 (en) | 2014-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02132A (forum.php) | ||
| MX2014015258A (es) | Variantes del factor 21 de crecimiento de fibroblasto. | |
| TN2014000096A1 (en) | Fibroblast growth factor 21 variants | |
| MX2012007806A (es) | Composiciones farmaceuticas para administracion oral de peptidos de insulina. | |
| IN2014KN02830A (forum.php) | ||
| MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
| MX346224B (es) | Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. | |
| EP3682875A3 (en) | Methods of treating pediatric metabolic syndrome | |
| UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
| IN2012DN06720A (forum.php) | ||
| WO2011084808A3 (en) | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases | |
| WO2012098562A3 (en) | Liquid oral compositions of lanthanum salts | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| TN2014000046A1 (en) | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | |
| IN2014DN09297A (forum.php) | ||
| IN2012DN00239A (forum.php) | ||
| TN2015000267A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| EP4385563A3 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| GB201108343D0 (en) | Honey composition | |
| MY197454A (en) | Non-enteric pharmaceutical composition comprising crofelemer | |
| IL230751A0 (en) | New peptides, preparations containing them and used in methods to treat metabolic, cardiac and immune diseases | |
| UA112981C2 (uk) | Варіант людського gdnf | |
| GB201115977D0 (en) | Neurodevelopmental disorders | |
| WO2011154975A3 (en) | Pharmaceutical compositions of metformin |